<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146027</url>
  </required_header>
  <id_info>
    <org_study_id>YAKULT</org_study_id>
    <nct_id>NCT02146027</nct_id>
  </id_info>
  <brief_title>Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients Infected Patients</brief_title>
  <official_title>Immunological Effects of Continuous, Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients on Suppressive Antiretroviral Treatment With Poor CD4+ T-cell Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yakult Honsha Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, HIV-infected patients with poor recovery of CD4+ T cells and successful viral
      control after treatment with antiretroviral therapy will be enrolled to receive once a day
      Lactobcillus casei Shirota or placebo in a double-blind, randomized fashion. Immune
      parameters will be monitored for 12 weeks in both arms.

      The main outcome is CD4+ T cell recovery. Secondary outcomes will include NK cells and T
      cells immune parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, HIV-infected patients with poor recovery of CD4+ T cells and successful viral
      control after treatment with antiretroviral therapy will be enrolled to receive once a day
      Lactobcillus casei Shirota or placebo in a double-blind, randomized fashion.

      The main objective is to investigate whether the continuous, once a day, 12-weeks use of
      Yakult product containing Lactobacillus casei Shirota could affect immunological parameters
      in HIV-infected patients on suppressive antiretroviral treatment with poor CD4+ T cell
      recovery. A total of 48 volunteers will be followed for 12 week after initiation of daily use
      of Lactobcillus casei Shirota or placebo, randomized in a 1:1 ratio.

      We hypothesize that use of the Yakult product containing Lactobacillus casei Shirota after 12
      weeks of continuous use will increase the level of CD4+ T-cells, at least, 50 cells/mm³.

      We also propose to investigate several markers of immune response, including T cellular
      activation and NK cells function, and changes in the intestinal microbiota.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase between baseline and after 6 weeks and 12 weeks in the absolute CD4+ T-cell count in active and placebo group.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Only differences greater than 50 T CD4+ cells/mm³ would be included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in level of cell activation at week 12 count</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>Cell activation will be accessed by flow cytometry assays in a FACSCanto flow cytometer, using the following monoclonal antibodies: CD3, CD4, CD8, CD38, CCR5, CD69, anti-HLA-DR+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in level of cell activation at week 6</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>Cell activation will be accessed by flow cytometry assays in a FACSCanto flow cytometer, using the following monoclonal antibodies: CD3, CD4, CD8, CD38, CCR5, CD69, anti-HLA-DR+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NK cytototoxic activity against K562 cells at week 6</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>NK cell phenotyping and function will be assessed according to Long et al., were subpopulations of NK cells will be assessed by the expression of CD56, CD16 molecules in the CD3-CD14-CD20- population of mononuclear cells. Production of IFNgama and CD103a proteins will be evaluated by flow cytometry in K562 stimulated mononuclear cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NK cytototoxic activity against K562 cells at week 12</measure>
    <time_frame>baseline, week 12</time_frame>
    <description>NK cell phenotyping and function will be assessed according to Long et al., were subpopulations of NK cells will be assessed by the expression of CD56, CD16 molecules in the CD3-CD14-CD20- population of mononuclear cells. Production of IFNgama and CD103a proteins will be evaluated by flow cytometry in K562 stimulated mononuclear cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Intestinal symptoms score of the Inflammatory Bowel Disease Questionnaire (IBQD) at week 12</measure>
    <time_frame>baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the intestinal microbiome in the participants taking Lactobacillus casei Shirota at week 12</measure>
    <time_frame>baseline, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events reasonable causal relationship with the study product in active and placebo groups</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma sCD4 levels at week 6</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>CD14 levels will be measured using commercially available kits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma sCD4 levels at week 12</measure>
    <time_frame>baseline, week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Fermented Milk Drink Yakult 40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus casei Shirota, contained in the Fermented Milk Drink Yakult 40
Once daily Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo would be an analogous product without Live Lactic Bacteria (Lactobacillus casei Shirota) presented in the same bottle and similar flavor.
Both, Yakult 40 and placebo should be stored refrigerated between 1° and 10°C and</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fermented Milk Drink Yakult 40</intervention_name>
    <description>Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks.</description>
    <arm_group_label>Fermented Milk Drink Yakult 40</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Yakult</other_name>
    <other_name>Live Lactic Bacteria (Lactobacillus casei Shirota)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fermented Milk Drink Yakult 40</intervention_name>
    <description>Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.</description>
    <arm_group_label>Fermented Milk Drink Yakult 40</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Live Lactic Bacteria (Lactobacillus casei Shirota)</other_name>
    <other_name>Yakult</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female HIV-1 infected patients aged between 18 and 60 years.

          -  Patient on suppressive antiretroviral treatment with poor CD4+ T-cell recovery.

          -  No change in antiretroviral therapy in the last six months or intended change in the
             next 12 weeks.

          -  Availability for the study procedures during the study period.

          -  Giving informed consent to participate in the study

        Exclusion Criteria:

          -  Diagnosis of any concomitant infections or diseases that might affect immunity or
             natural history of HIV-1 infection including active Hepatitis B infection, Hepatitis C
             infection, diabetes mellitus, neoplasias and autoimmune diseases.

          -  Use of treatments that might affect immunity in the last four weeks including
             immunomodulators, corticosteroids (only systemic use for two weeks or more), or
             antineoplasic agents.

          -  History of intolerance or allergy to cow milk or any other component of the study
             product including lactose intolerance, casein allergy, etc.

          -  Pregnancy, nursing mother or intention of became pregnant during the study period
             (only female participants).

          -  Unable to safely store the study product at home in the conditions recommended by the
             manufacturer.

          -  Any other condition that might interfere with the study procedure according to the
             investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esper G Kallás, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Sao Paulo - General Hospital</name>
      <address>
        <city>São Paulo</city>
        <zip>01246-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006 Jun;83(6):1256-64; quiz 1446-7. Review.</citation>
    <PMID>16762934</PMID>
  </results_reference>
  <results_reference>
    <citation>Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008 Jan;1(1):23-30. doi: 10.1038/mi.2007.1. Review.</citation>
    <PMID>19079157</PMID>
  </results_reference>
  <results_reference>
    <citation>Corazza GR, Ginaldi L, Furia N, Marani-Toro G, Di Giammartino D, Quaglino D. The impact of HIV infection on lactose absorptive capacity. J Infect. 1997 Jul;35(1):31-5.</citation>
    <PMID>9279721</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition. 2009 May;25(5):520-5. doi: 10.1016/j.nut.2008.11.017. Epub 2009 Feb 8.</citation>
    <PMID>19201576</PMID>
  </results_reference>
  <results_reference>
    <citation>Hummelen R, Vos AP, van't Land B, van Norren K, Reid G. Altered host-microbe interaction in HIV: a target for intervention with pro- and prebiotics. Int Rev Immunol. 2010 Oct;29(5):485-513. doi: 10.3109/08830185.2010.505310. Review.</citation>
    <PMID>20839912</PMID>
  </results_reference>
  <results_reference>
    <citation>Irvine SL, Hummelen R, Hekmat S, Looman CW, Habbema JD, Reid G. Probiotic yogurt consumption is associated with an increase of CD4 count among people living with HIV/AIDS. J Clin Gastroenterol. 2010 Oct;44(9):e201-5. doi: 10.1097/MCG.0b013e3181d8fba8.</citation>
    <PMID>20463586</PMID>
  </results_reference>
  <results_reference>
    <citation>Marchetti G, Bellistrì GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G, Gori A, Monforte AD. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008 Oct 1;22(15):2035-8. doi: 10.1097/QAD.0b013e3283112d29.</citation>
    <PMID>18784466</PMID>
  </results_reference>
  <results_reference>
    <citation>Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'arminio Monforte A; ICONA Foundation Study Group. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011 Jul 17;25(11):1385-94. doi: 10.1097/QAD.0b013e3283471d10.</citation>
    <PMID>21505312</PMID>
  </results_reference>
  <results_reference>
    <citation>Massanella M, Negredo E, Pérez-Alvarez N, Puig J, Ruiz-Hernández R, Bofill M, Clotet B, Blanco J. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS. 2010 Apr 24;24(7):959-68. doi: 10.1097/QAD.0b013e328337b957.</citation>
    <PMID>20177358</PMID>
  </results_reference>
  <results_reference>
    <citation>Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J, Gonzalez-Canali G, Jayle D, Karmochkine M, Weiss L, Aboulker JP, Kazatchkine MD. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998 May 7;12(7):745-50.</citation>
    <PMID>9619806</PMID>
  </results_reference>
  <results_reference>
    <citation>Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub TE, Davenport M, Crowe S, Elliott J, Hoy J, Fairley C, Stewart G, Cameron P, Lewin SR. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J Infect Dis. 2010 Oct 15;202(8):1254-64. doi: 10.1086/656369.</citation>
    <PMID>20812848</PMID>
  </results_reference>
  <results_reference>
    <citation>Trois L, Cardoso EM, Miura E. Use of probiotics in HIV-infected children: a randomized double-blind controlled study. J Trop Pediatr. 2008 Feb;54(1):19-24. Epub 2007 Sep 17.</citation>
    <PMID>17878180</PMID>
  </results_reference>
  <results_reference>
    <citation>Tinmouth J, Kandel G, Tomlinson G, Walmsley S, Steinhart AH, Glazier R. The effect of dairy product ingestion on human immunodeficiency virus-related diarrhea in a sample of predominantly gay men: a randomized, controlled, double-blind, crossover trial. Arch Intern Med. 2006 Jun 12;166(11):1178-83.</citation>
    <PMID>16772244</PMID>
  </results_reference>
  <results_reference>
    <citation>Woelk CH, Beliakova-Bethell N, Goicoechea M, Zhao Y, Du P, Rought SE, Lozach J, Pérez-Santiago J, Richman DD, Smith DM, Little SJ. Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery. AIDS. 2010 Jan 16;24(2):217-22. doi: 10.1097/QAD.0b013e328334f1f0.</citation>
    <PMID>19952713</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Esper Georges Kallás</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Lactobacillus casei Shirota</keyword>
  <keyword>NK cell</keyword>
  <keyword>CD4</keyword>
  <keyword>Lymphocyte</keyword>
  <keyword>Cell activation</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Immune discordants</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

